Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1320-1326

  Eyler, Rachel F ^a   Vilay, A Mary ^b   Nader, Ahmed M ^c   Heung, Michael ^d,e   Pleva, Melissa ^e   Sowinski, Kevin M ^f   DePestel, Daryl D ^g   Sörgel, Fritz ^h,i   Kinzig, Martina ^h   Mueller, Bruce A ^j  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c Qatar University College of Pharmacy ^*  (Qatar)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f PURDUE UNIVERSITY   (United States)

^g CUBIST PHARMACEUTICALS INC   (United States)

^h Institute for Biomedical and Pharmaceutical Research   (Germany)

ⁱ UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^j UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMODIALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG INFUSION; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; MALE; MIDDLE AGED; MONTE CARLO METHOD; PRIORITY JOURNAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CRITICAL ILLNESS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMOFILTRATION; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84896857022     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02090-12     Document Type: Article

References (34)

1. Merck & Co., Inc. 2010. Ertapenem package insert. Merck & Co., Inc., White-house Station, NJ. http://www.merck.com/product/usa/pi-circulars/i/ invanz/invanz-pi.pdf.
2. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C, Beginning and Ending Supportive Therapy for the Kidney (BEST-Kidney) Investigators. 2005. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813-818. http://dx.doi.org/10.1001/jama.294.7.813.
3. Majumdar AK, Musson DG, Birk KL, Kitchen CJ, Holland S, McCrea J, Mistry G, Hesney M, Xi L, Li SX, Haesen R, Blum RA, Lins RL, Greenberg H, Waldman S, Deutsch P, Rogers JD. 2002. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob. Agents Chemother. 46:3506-3511. http://dx.doi.org/10. 1128/AAC.46.11.3506-3511.2002. (Pubitemid 35192918)
4. Musson DG, Majumdar A, Holland S, Birk K, Xi L, Mistry G, Sciberras D, Muckow J, Deutsch P, Rogers JD. 2004. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob. Agents Chemother. 48:521-524. http://dx.doi.org/10.1128/AAC.48.2.521-524.2004. (Pubitemid 38141711)
5. Stevenson JM, Patel JH, Churchwell MD, Vilay AM, Depestel DD, Sörgel F, Kinzig M, Jakob V, Mueller BA. 2008. Ertapenem clearance during modeled continuous renal replacement therapy. Int. J. Artif. Organs 31:1027-1034.
6. Boucher BA, Wood GC, Swanson JM. 2006. Pharmacokinetic changes in critical illness. Crit. Care Clin. 22:255-271. http://dx.doi.org/10.1016/j.ccc. 2006.02.011.
7. Sánchez M, Jiménez-Lendínez M, Cidoncha M, Asensio MJ, Herrerot E, Collado A, Santacruz M. 2011. Comparison of fluid compartments and fluid responsiveness in septic and non-septic patients. Anaesth. Intensive Care 39:1022-1029.
8. Van Dalen R, Vree TB, Baars IM. 1987. Influence of protein binding and severity of illness on renal elimination of four cephalosporin drugs in intensive-care patients. Pharm. Weekbl. Sci. 9:98-103. http://dx.doi.org/10. 1007/BF01960743. (Pubitemid 17046705)
9. Zielmann S, Mielck F, Kahl R, Kazmaier S, Sydow M, Kolk J, Burchardi H. 1994. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther. Drug Monit. 16:139-144. http://dx.doi.org/10.1097/00007691-199404000-00005. (Pubitemid 24096618)
10. Zamacona MK, Suárez E, Aguilera L, Rodríguez-Sasiaín Aguirre C, Calvo R. 1997. Serum protein binding of propofol in critically ill patients. Acta Anaesthesiol. 41:1267-1272. http://dx.doi.org/10.1111/j.1399- 6576.1997.tb04643.x. (Pubitemid 27517657)
11. Eyler RF, Vilay AM, Heung M, Pleva M, Sowinski KM, DePestel DD, Mueller BA. 2011. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis (CVVHD) or hemodiafiltration (CVVHDF). J. Am. Soc. Nephrol. 22:314A.
12. Swartz R, Pasko D, O'Toole J, Starmann B. 2004. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin. Nephrol. 61:134-143. http://dx.doi.org/10.5414/CNP61134. (Pubitemid 38219910)
13. Vilay AM, Grio M, Depestel DD, Sowinski KM, Gao L, Heung M, Salama NN, Mueller BA. 2011. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit. Care Med. 39:19-25. http://dx.doi.org/10.1097/CCM.0b013e3181fa36fb.
14. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions "bug and drug." Nat. Rev. Microbiol. 2:289-300. http://dx.doi.org/10. 1038/nrmicro862. (Pubitemid 39490099)
15. Varghese JM, Roberts JA, Lipman J. 2011. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit. Care Clin. 27:19-34. http://dx.doi.org/10.1016/j.ccc.2010.09.006.
16. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. 2011. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin. Pharmacokinet. 50:99-110. http://dx.doi.org/10.2165/11539220- 000000000-00000.
17. Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J. 2010. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J. Antimicrob. Chemother. 65: 1771-1778. http://dx.doi.org/10.1093/jac/dkq184.
18. Zelenitsky SA, Ariano RE, Zhanel GG. 2011. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J. Antimicrob. Chemother. 66:343-349. http://dx.doi.org/10.1093/jac/dkq348.
19. Nix DE, Matthias KR, Ferguson EC. 2004. Effect of ertapenem protein binding on killing of bacteria. Antimicrob. Agents Chemother. 48:3419-3424. http://dx.doi.org/10.1128/AAC.48.9.3419-3424.2004. (Pubitemid 39129340)
20. Wexler HM. 2004. In vitro activity of ertapenem: review of recent studies. J. Antimicrob. Chemother. 53(Suppl 2):ii11-ii21. http://dx.doi.org/10. 1093/jac/dkh204.
21. Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, Welte T. 2007. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J. Antimicrob. Chemother. 59:277-284. http://dx.doi.org/10.1093/jac/dkl485. (Pubitemid 47072067)
22. Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J. 2009. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int. J. Antimicrob. Agents 33:432-436. http://dx.doi.org/10. 1016/j.ijantimicag.2008.10.005.
23. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F. 2011. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit. Care. 15:R137. http://dx.doi.org/10.1186/cc10257.
24. Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM. 2011. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob. Agents Chemother. 55:5868-5873. http://dx.doi.org/10.1128/AAC.00424-11.
25. Burkhardt O, Hafer C, Langhoff A, Kaever V, Kumar V, Welte T, Haller H, Fliser D, Kielstein JT. 2009. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol. Dial. Transplant. 24:267-271. http://dx.doi.org/10.1093/ndt/gfn472.
26. Li C, Du X, Kuti JL, Nicolau DP. 2007. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob. Agents Chemother. 51:1725-1730. http://dx.doi.org/10.1128/AAC.00294-06. (Pubitemid 46744151)
27. Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. 2005. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann. Pharmacother. 39:32-38. http://dx.doi.org/10.1345/aph.1E271. (Pubitemid 40052375)
28. McKinnon PS, Paladino JA, Schentag JJ. 2008. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int. J. Antimicrob. Agents 31:345-351. http://dx.doi.org/10.1016/j.ijantimicag.2007.12.009.
29. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. 2007. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int. J. Antimicrob. Agents 30:11-18. http://dx.doi.org/10.1016/j.ijantimicag. 2007.02.002. (Pubitemid 46874893)
30. Burkhardt O, Derendorf H, Welte T. 2007. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin. Pharmacother. 8:237-256. http://dx.doi.org/10.1517/14656566.8.2.237. (Pubitemid 46206625)
31. Seto AH, Song JC, Guest SS. 2005. Ertapenem-associated seizures in a peritoneal dialysis patient. Ann. Pharmacother. 39:352-356. http://dx.doi.org/ 10.1345/aph.1E421. (Pubitemid 40165228)
32. Choi G, Gomersall CD, Tian Q, Joynt GM, Li AM, Lipman J. 2009. Principles of antibacterial dosing in continuous renal replacement therapy. Crit. Care Med. 37:2268-2282. http://dx.doi.org/10.1097/CCM.0b013e3181aab3d0.
33. Kielstein JT, Burkhardt O. 2011. Dosing of antibiotics in critically ill patients undergoing renal replacement therapy. Curr. Pharm. Biotechnol. 12:2015-2019. http://dx.doi.org/10.2174/138920111798808275.
34. Kielstein JT. 2009. Dosage of renal replacement therapy in acute renal failure. Dtsch. Med. Wochenschr. 134:1697-1699. http://dx.doi.org/10.1055/s- 0029-1234005.